116 related articles for article (PubMed ID: 38706988)
1. Bortezomib promotes the TRAIL-mediated killing of resistant rhabdomyosarcoma by ErbB2/Her2-targeted CAR-NK-92 cells via DR5 upregulation.
Heim C; Hartig L; Weinelt N; Moser LM; Salzmann-Manrique E; Merker M; Wels WS; Tonn T; Bader P; Klusmann JH; van Wijk SJL; Rettinger E
Mol Ther Oncol; 2024 Jun; 32(2):200802. PubMed ID: 38706988
[TBL] [Abstract][Full Text] [Related]
2. ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma.
Merker M; Wagner J; Kreyenberg H; Heim C; Moser LM; Wels WS; Bonig H; Ivics Z; Ullrich E; Klingebiel T; Bader P; Rettinger E
Front Immunol; 2020; 11():581468. PubMed ID: 33193388
[TBL] [Abstract][Full Text] [Related]
3. ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma.
Heim C; Moser LM; Kreyenberg H; Bonig HB; Tonn T; Wels WS; Gradhand E; Ullrich E; Meister MT; Koerkamp MG; Holstege FCP; Drost J; Klusmann JH; Bader P; Merker M; Rettinger E
Front Immunol; 2023; 14():1228894. PubMed ID: 37662907
[TBL] [Abstract][Full Text] [Related]
4. CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation.
Eitler J; Rackwitz W; Wotschel N; Gudipati V; Murali Shankar N; Sidorenkova A; Huppa JB; Ortiz-Montero P; Opitz C; Künzel SR; Michen S; Temme A; Loureiro LR; Feldmann A; Bachmann M; Boissel L; Klingemann H; Wels WS; Tonn T
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38417916
[TBL] [Abstract][Full Text] [Related]
5. Retargeting of NK-92 Cells against High-Risk Rhabdomyosarcomas by Means of an ERBB2 (HER2/Neu)-Specific Chimeric Antigen Receptor.
Gossel LDH; Heim C; Pfeffermann LM; Moser LM; Bönig HB; Klingebiel TE; Bader P; Wels WS; Merker M; Rettinger E
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33809981
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity.
Lundqvist A; Abrams SI; Schrump DS; Alvarez G; Suffredini D; Berg M; Childs R
Cancer Res; 2006 Jul; 66(14):7317-25. PubMed ID: 16849582
[TBL] [Abstract][Full Text] [Related]
7. Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis.
Petak I; Douglas L; Tillman DM; Vernes R; Houghton JA
Clin Cancer Res; 2000 Oct; 6(10):4119-27. PubMed ID: 11051265
[TBL] [Abstract][Full Text] [Related]
8. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
[TBL] [Abstract][Full Text] [Related]
9. The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells.
Feng X; Yan J; Wang Y; Zierath JR; Nordenskjöld M; Henter JI; Fadeel B; Zheng C
Mol Immunol; 2010 Aug; 47(14):2388-96. PubMed ID: 20542572
[TBL] [Abstract][Full Text] [Related]
10. NK92 Expressing Anti-BCMA CAR and Secreted TRAIL for the Treatment of Multiple Myeloma: Preliminary In Vitro Assessment.
Motais B; Charvátová S; Walek Z; Hájek R; Bagó JR
Cells; 2023 Nov; 12(23):. PubMed ID: 38067177
[TBL] [Abstract][Full Text] [Related]
11. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition.
Hallett WH; Ames E; Motarjemi M; Barao I; Shanker A; Tamang DL; Sayers TJ; Hudig D; Murphy WJ
J Immunol; 2008 Jan; 180(1):163-70. PubMed ID: 18097016
[TBL] [Abstract][Full Text] [Related]
12. Synergistic apoptosis of human gastric cancer cells by bortezomib and TRAIL.
Bui HTT; Le NH; Le QA; Kim SE; Lee S; Kang D
Int J Med Sci; 2019; 16(11):1412-1423. PubMed ID: 31673231
[TBL] [Abstract][Full Text] [Related]
13. The Smac Mimetic BV6 Improves NK Cell-Mediated Killing of Rhabdomyosarcoma Cells by Simultaneously Targeting Tumor and Effector Cells.
Fischer K; Tognarelli S; Roesler S; Boedicker C; Schubert R; Steinle A; Klingebiel T; Bader P; Fulda S; Ullrich E
Front Immunol; 2017; 8():202. PubMed ID: 28326081
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex.
Brooks AD; Jacobsen KM; Li W; Shanker A; Sayers TJ
Mol Cancer Res; 2010 May; 8(5):729-38. PubMed ID: 20442297
[TBL] [Abstract][Full Text] [Related]
15. Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting.
Eitler J; Wotschel N; Miller N; Boissel L; Klingemann HG; Wels W; Tonn T
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33468562
[TBL] [Abstract][Full Text] [Related]
16. Effects of bortezomib in sensitizing human prostate cancer cell lines to NK-mediated cytotoxicity.
Hu W; Zheng RR; Cui HX; Yue D; Wang Y; Jiang YH
Asian J Androl; 2012 Sep; 14(5):695-702. PubMed ID: 22902909
[TBL] [Abstract][Full Text] [Related]
17. Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition.
Ames E; Hallett WH; Murphy WJ
Clin Exp Immunol; 2009 Mar; 155(3):504-13. PubMed ID: 19220837
[TBL] [Abstract][Full Text] [Related]
18. Role of NKG2D, DNAM-1 and natural cytotoxicity receptors in cytotoxicity toward rhabdomyosarcoma cell lines mediated by resting and IL-15-activated human natural killer cells.
Boerman GH; van Ostaijen-ten Dam MM; Kraal KC; Santos SJ; Ball LM; Lankester AC; Schilham MW; Egeler RM; van Tol MJ
Cancer Immunol Immunother; 2015 May; 64(5):573-83. PubMed ID: 25854581
[TBL] [Abstract][Full Text] [Related]
19. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.
Zhang C; Burger MC; Jennewein L; Genßler S; Schönfeld K; Zeiner P; Hattingen E; Harter PN; Mittelbronn M; Tonn T; Steinbach JP; Wels WS
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26640245
[TBL] [Abstract][Full Text] [Related]
20. Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor.
Schönfeld K; Sahm C; Zhang C; Naundorf S; Brendel C; Odendahl M; Nowakowska P; Bönig H; Köhl U; Kloess S; Köhler S; Holtgreve-Grez H; Jauch A; Schmidt M; Schubert R; Kühlcke K; Seifried E; Klingemann HG; Rieger MA; Tonn T; Grez M; Wels WS
Mol Ther; 2015 Feb; 23(2):330-8. PubMed ID: 25373520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
